LAUSR

Mitoxantrone (MTO) is clinically utilized for treating hormone‐refractory prostate cancer (PCa), however, the therapeutic outcome is far from optimal due to the lack of proper drug carrier as well as the inherent MTO detoxification mechanisms of DNA lesion repair and anti‐oxidation. Herein, a bombesin‐installed nanoplatform combining the chemotherapeutic MTO and the chemotherapeutic sensitizer of nitric oxide (NO) is developed based on MTO‐loaded macromolecular NO‐donor‐containing polymeric micelles (BN‐NMMTO) for targeted NO‐sensitized chemotherapy against PCa. BN‐NMMTO actively target and accumulates in PCa sites and are internalized into the tumor cells. The macromolecular NO‐donor of BN‐NMMTO undergoes a reductive reaction to unleash NO upon intracellular glutathione (GSH), accompanying by micelle swelling and MTO release. The targeted intracellular MTO release induces DNA lesion and reactive oxygen species (ROS) generation in tumor cells without damage to the normal cells, and MTO's cytotoxicity is further augmented by NO release via the inhibition of both DNA repair and anti‐oxidation pathways as compared with traditional MTO therapies.